Cargando…

Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4‐MYC oncogenic axis in multiple myeloma

B‐cell progenitor fate determinant interferon regulatory factor 4 (IRF4) exerts key roles in the pathogenesis and progression of multiple myeloma (MM), a currently incurable plasma cell malignancy. Aberrant expression of IRF4 and the establishment of a positive auto‐regulatory loop with oncogene MYC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Agnarelli, Alessandro, Mitchell, Simon, Caalim, Gillian, Wood, C. David, Milton‐Harris, Leanne, Chevassut, Timothy, West, Michelle J., Mancini, Erika J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543246/ https://www.ncbi.nlm.nih.gov/pubmed/35544413 http://dx.doi.org/10.1002/hon.3016

Ejemplares similares

Oncogene addiction to c-MYC in myeloma cells
por: Holien, Toril, et al.
Publicado: (2012)

CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC regulatory axis in proliferation
por: Garcia-Carpizo, Veronica, et al.
Publicado: (2018)

Phosphorus and sulfur SAD phasing of the nucleic acid-bound DNA-binding domain of interferon regulatory factor 4
por: Agnarelli, Alessandro, et al.
Publicado: (2021)

BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1
por: Stewart, Helen Jayne Susan, et al.
Publicado: (2013)

Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition
por: Graziani, Vittoria, et al.
Publicado: (2023)

Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma
por: Bolin, Sara, et al.
Publicado: (2018)

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
por: Díaz, Tania, et al.
Publicado: (2017)

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors
por: Tolani, Bhairavi, et al.
Publicado: (2013)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma
por: Faruq, Omar, et al.
Publicado: (2022)

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Kandela, Irawati, et al.
Publicado: (2015)

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Aird, Fraser, et al.
Publicado: (2017)

Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis
por: Ishiguro, Kazuya, et al.
Publicado: (2021)

Small molecule inhibits T-cell acute lymphoblastic leukaemia oncogenic interaction through conformational modulation of LMO2
por: Milton-Harris, Leanne, et al.
Publicado: (2020)

The 5T mouse multiple myeloma model: absence of c-myc oncogene rearrangement in early transplant generations.
por: Radl, J., et al.
Publicado: (1990)

Correction: Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
por: Aird, Fraser, et al.
Publicado: (2018)

MYC inhibitors in multiple myeloma
por: Martínez-Martín, Sandra, et al.
Publicado: (2021)

Oncogenic MYC amplifies mitotic perturbations
por: Littler, Samantha, et al.
Publicado: (2019)

The Genetic Architecture of Multiple Myeloma
por: Prideaux, Steven M., et al.
Publicado: (2014)

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
por: Bandopadhayay, Pratiti, et al.
Publicado: (2019)

Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells
por: Otto, C., et al.
Publicado: (2019)

Dissecting transcriptional amplification by MYC
por: Nie, Zuqin, et al.
Publicado: (2020)

Crosstalk between b-catenin and WT1 signaling activity in acute myeloid leukemia
por: Wagstaff, Megan, et al.
Publicado: (2022)

Coamplification of the L‐myc and N‐myc Oncogenes in a Neuroblastoma Cell Line
por: Jinbo, Takeshi, et al.
Publicado: (1989)

Therapeutically targeting oncogenic CRCs facilitates induced differentiation of NB by RA and the BET bromodomain inhibitor
por: Alleboina, Satyanarayana, et al.
Publicado: (2021)

MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2015)

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

Anaplastic multiple myeloma with MYC rearrangement
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Myc, Oncogenic Protein Translation, and the Role of Polyamines
por: Flynn, Andrea T., et al.
Publicado: (2018)

The OTUD6B‐LIN28B‐MYC axis determines the proliferative state in multiple myeloma
por: Paulmann, Carmen, et al.
Publicado: (2022)

Maintenance of MYC expression promotes de novo resistance to BET bromodomain inhibition in castration-resistant prostate cancer
por: Coleman, Daniel J., et al.
Publicado: (2019)

PIK3CA Cooperates with KRAS to Promote MYC Activity and Tumorigenesis via the Bromodomain Protein BRD9
por: Bell, Catherine M., et al.
Publicado: (2019)

High Intrinsic Oncogenic Potential in the Myc-Box-Deficient Hydra Myc3 Protein
por: Lechable, Marion, et al.
Publicado: (2023)

Suppression of interferon β gene transcription by inhibitors of bromodomain and extra-terminal (BET) family members
por: Malik, Nazma, et al.
Publicado: (2015)

Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Correction: MYC amplifications in myeloma cell lines: correlation with MYC-inhibitor efficacy
por: Holien, Toril, et al.
Publicado: (2018)

Selective inhibition of BET bromodomains
por: Filippakopoulos, Panagis, et al.
Publicado: (2010)

PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc
por: Li, Zhiheng, et al.
Publicado: (2020)

Detection of the c-myc oncogene product in testicular cancer.
por: Sikora, K., et al.
Publicado: (1985)

Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency
por: Barna, Maria, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_0ii2i7ai5f5q0cqo7i31ctf9u2